Nicolas Villain

5.1k total citations · 2 hit papers
68 papers, 2.7k citations indexed

About

Nicolas Villain is a scholar working on Physiology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Nicolas Villain has authored 68 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Physiology, 36 papers in Psychiatry and Mental health and 17 papers in Cognitive Neuroscience. Recurrent topics in Nicolas Villain's work include Alzheimer's disease research and treatments (36 papers), Dementia and Cognitive Impairment Research (32 papers) and Functional Brain Connectivity Studies (11 papers). Nicolas Villain is often cited by papers focused on Alzheimer's disease research and treatments (36 papers), Dementia and Cognitive Impairment Research (32 papers) and Functional Brain Connectivity Studies (11 papers). Nicolas Villain collaborates with scholars based in France, United States and Sweden. Nicolas Villain's co-authors include Gaël Chételat, Francis Eustache, Vincent de La Sayette, Béatrice Desgranges, Brigitte Landeau, Bruno Dubois, Renaud La Joie, Vincent Planche, Florence Mézenge and Jean‐Claude Baron and has published in prestigious journals such as The Lancet, Journal of Neuroscience and PLoS ONE.

In The Last Decade

Nicolas Villain

62 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

2021 598 citations Bruno Dubois, Nicolas Villain et al. profile →
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics

2025 15 citations Nicolas Villain, Vincent Planche et al. The Journal of Prevention of Alzheimer s Disease profile →

Peers

Countries citing papers authored by Nicolas Villain

Since Specialization

Citations

This map shows the geographic impact of Nicolas Villain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Villain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Villain more than expected).

Fields of papers citing papers by Nicolas Villain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Villain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Villain. The network helps show where Nicolas Villain may publish in the future.

Co-authorship network of co-authors of Nicolas Villain

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Villain. A scholar is included among the top collaborators of Nicolas Villain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Villain. Nicolas Villain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Iatrogenic Cerebral Amyloid Angiopathy After Cardiac Surgery 2026 ·Neurology ·(unknown), (unknown), (unknown), (unknown), Nicolas Villain, (unknown), Aurélie Kas, (unknown)	0
2	The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence 2025 ·Alzheimer s & Dementia ·Vincent Planche, Suzanne E. Schindler, David S. Knopman, Giovanni B. Frisoni, Douglas Galasko, Joshua D. Grill, Lon S. Schneider, Jason Karlawish, Nicolas Villain	4
3	Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics breakdown → 2025 ·The Journal of Prevention of Alzheimer s Disease ·Nicolas Villain, Vincent Planche, Matthieu Lilamand, Charlotte Cordonnier, Maria Soto‐Martin, (unknown), Stéphanie Bombois, Julien Delrieu	15
4	Scenarios for the long‐term efficacy of amyloid‐targeting therapies in the context of the natural history of Alzheimer's disease 2024 ·Alzheimer s & Dementia ·Lars Lau Rakêt, (unknown), Alexis Moscoso, Nicolas Villain, Michael Schöll	6
5	What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries 2024 ·European Journal of Neurology ·Nicolas Villain, (unknown)	13
6	Disentangling clinical and biological trajectories of neurodegenerative diseases 2024 ·Nature Reviews Neurology ·Nicolas Villain, Vincent Planche	11
7	Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome 2024 ·Acta Neuropathologica ·(unknown), Elena Camporesi, Eleni Gkanatsiou, Susana Boluda, Gunnar Brinkmalm, Lev Stimmer, Junyue Ge, Jörg Hanrieder, Nicolas Villain, Charles Duyckaerts, Yannick Vermeiren, Sarah E. Pape, Gaël Nicolas, Annie Laquerrière, Peter Paul De Deyn, David Wallon, Kaj Blennow, André Strydom, Henrik Zetterberg, Marie‐Claude Potier	5
8	Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease 2023 ·Brain Communications ·Kathy Liu, Nicolas Villain, Scott Ayton, Sarah F. Ackley, Vincent Planche, Robert Howard, Madhav Thambisetty	32
9	A Comparison Between Early Presentation of Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease: Evidence from Routine Primary Care and UK Biobank Data 2023 ·Annals of Neurology ·(unknown), Baptiste Couvy‐Duchesne, (unknown), Raphaël Couronné, (unknown), (unknown), (unknown), Yeda Wu, Nicolas Villain, Anette Schrag, Stanley Durrleman, Jean‐Christophe Corvol	14
10	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France 2022 ·Revue Neurologique ·Nicolas Villain, Vincent Planche, Raymond Levy	14
11	Association of APOE -Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults 2022 ·Neurology ·Laura Xicota, Beata Gyorgy, Benjamin Grenier‐Boley, (unknown), Gaëlle Fontaine, Fabrice Danjou, (unknown), Olivier Colliot, Philippe Amouyel, (unknown), Marcel Lévy, Nicolas Villain, Marie‐Odile Habert, Bruno Dubois, Jean‐Charles Lambert, Marie‐Claude Potier, (unknown)	8
12	Actualités thérapeutiques dans la maladie d’Alzheimer : bientôt un traitement de fond ? 2022 ·PubMed ·Nicolas Villain	1
13	NeuroQ: A neurophobia screening tool assesses how roleplay challenges neurophobia 2021 ·Journal of the Neurological Sciences ·Eavan McGovern, Céline Louapre, Julien Cassereau, Constance Flamand‐Roze, (unknown), Prasanthi Jegatheesan, David Bendetowicz, (unknown), (unknown), Nicolas Villain, (unknown), Paul Sauleau, Laure Michel, Marc Vérin, Yulia Worbe, Bruno Falissard, Emmanuel Roze	14
14	Pour une prise en charge préventive de la maladie d’Alzheimer 2020 ·Bulletin de l Académie Nationale de Médecine ·Bruno Dubois, (unknown), Nicolas Villain, Marc Teichmann, Stéphane Epelbaum, Raffaella Migliaccio, (unknown), (unknown), (unknown), Marcel Lévy, Isabelle Le Ber, Rachel Lévy	1
15	Carotid contrast-enhanced ultrasonography and multimodal imaging in a case of TIPIC syndrome 2018 ·Revue Neurologique ·(unknown), Nicolas Villain, J.-M. Baud, (unknown), Fernando Pico	7
16	Social huddling and physiological thermoregulation are related to melanism in the nocturnal barn owl 2015 ·Oecologia ·Amélie N. Dreiss, Robin Séchaud, (unknown), Nicolas Villain, Michel Genoud, Bettina Almasi, Lukas Jenni, Alexandre Roulin	33
17	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease 2013 ·NeuroImage Clinical ·Gaël Chételat, Renaud La Joie, Nicolas Villain, Audrey Perrotin, Vincent de La Sayette, Francis Eustache, Rik Vandenberghe	263
18	Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study 2012 ·Brain ·Nicolas Villain, Gaël Chételat, Blandine Grassiot, Pierrick Bourgeat, Gareth Jones, Kathryn A. Ellis, David Ames, Ralph N. Martins, Francis Eustache, Olivier Salvado, Colin L. Masters, Christopher C. Rowe, Victor L. Villemagne	195
19	Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence 2010 ·NeuroImage ·Renaud La Joie, Marine Fouquet, Florence Mézenge, Brigitte Landeau, Nicolas Villain, Katell Mevel, Alice Pèlerin, Francis Eustache, Béatrice Desgranges, Gaël Chételat	137
20	Relationships between Hippocampal Atrophy, White Matter Disruption, and Gray Matter Hypometabolism in Alzheimer's Disease 2008 ·Journal of Neuroscience ·Nicolas Villain, Béatrice Desgranges, Fausto Viader, Vincent de La Sayette, Florence Mézenge, Brigitte Landeau, Jean‐Claude Baron, Francis Eustache, Gaël Chételat	298

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact